Taiho Oncology, Inc.
Kangho Daniel Ko is a Senior Director at Taiho Oncology, Inc. with extensive experience in new product planning, business development, and market research. Prior to this role, Ko worked at Eli Lilly and Company in various positions including Director Corporate Business Development and Associate Brand Manager for Global/US Oncology. Ko also has experience in global payer market research and sales representation for Lilly Diabetes. Additionally, Ko served as a Ground Intelligence Officer in the United States Marine Corps. Ko holds an MBA from The Tuck School of Business at Dartmouth and a BA in Economics/International Area Studies from UCLA.
This person is not in any teams
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com